Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 21:16:1592733.
doi: 10.3389/fimmu.2025.1592733. eCollection 2025.

Advancements and challenges in immunotherapy for gastric cancer: current approaches and future directions

Affiliations
Review

Advancements and challenges in immunotherapy for gastric cancer: current approaches and future directions

Wenyu Zhang et al. Front Immunol. .

Abstract

Gastric cancer (GC) poses a major global health challenge, marked by high incidence and mortality rates. Conventional treatments such as surgery, chemotherapy, and targeted therapies show limited effectiveness in patients at advanced stages. As a result, immunotherapy has emerged as a promising strategy in the battle against cancer. In recent years, immunotherapy has flourished, with immune checkpoint inhibitors becoming widely applied in GC, while other immunotherapies are also rapidly advancing in clinical development, providing new therapeutic options for patients. The introduction of immunotherapy has profoundly changed the approach to GC treatment, with the expectation that additional immunotherapies will be developed in the near future. However, the clinical effectiveness of these therapies remains constrained due to the complexity of the tumor microenvironment (TME) in GC, the significant heterogeneity among patients, as well as the occurrence of immune therapy resistance and adverse reactions. This review provides an overview of recent advancements in GC immunotherapy, focusing on ICIs, adoptive cell therapy, and tumor vaccines. Key challenges such as patient selection, biomarker development, and combination therapy optimization are also discussed. In the future, a deeper exploration of the TME characteristics of GC and the implementation of personalized and precise immunotherapy are expected to further improve therapeutic outcomes and patient prognosis.

Keywords: adoptive cell therapy; gastric cancer; immune checkpoint inhibitors; immunotherapy; oncolytic viruses; tumor microenvironment; tumor vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Novel immunotherapy techniques in gastric cancer: A visual summary of various immunotherapeutic strategies for gastric cancer and their mechanisms of action in cancer treatment. Includes ICIs, various therapeutic modalities for ACT, tumor vaccine therapies, and lysovirus therapies.
Figure 2
Figure 2
The tumor microenvironment in gastric cancer: Shows the complex interactions between various immune and non-immune cells surrounding the tumor.

Similar articles

References

    1. Koustas E, Trifylli EM, Sarantis P, Papadopoulos N, Karapedi E, Aloizos G, et al. . Immunotherapy as a therapeutic strategy for gastrointestinal cancer—Current treatment options and future perspectives. IJMS. (2022) 23:6664. doi: 10.3390/ijms23126664 - DOI - PMC - PubMed
    1. Cao W, Qin K, Li F, Chen W. Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN). J Natl Cancer Cent. (2024) 4:128–34. doi: 10.1016/j.jncc.2024.05.001 - DOI - PMC - PubMed
    1. Zhao JK, Wu M, Kim CH, Jin ZY, Zhou JY, Han RQ, et al. . Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province, China. Eur J Cancer Prev. (2017) 26:357–64. doi: 10.1097/CEJ.0000000000000262 - DOI - PMC - PubMed
    1. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. (2014) 23:700–13. doi: 10.1158/1055-9965.EPI-13-1057 - DOI - PMC - PubMed
    1. Yusefi AR, Bagheri Lankarani K, Bastani P, Radinmanesh M, Kavosi Z. Risk factors for gastric cancer: A systematic review. Asian Pac J Cancer Prev. (2018) 19:591–603. doi: 10.22034/APJCP.2018.19.3.591 - DOI - PMC - PubMed

MeSH terms

Substances